Otsuka Pharmaceutical Buys Mass. Biotech For $430M In Cash
Japan's Otsuka Pharmaceutical Co. Ltd. has agreed to buy private equity-backed, Massachusetts-based clinical stage biotechnology company Visterra Inc. for $430 million in cash in a deal already approved by both their...To view the full article, register now.
Already a subscriber? Click here to view full article